Women’s heart health across the lifespan is shaped by decades of hormonal, metabolic, and biological change — and cardiovascular disease remains the leading cause of death in women worldwide.
Hormonal changes and heart disease in women are closely linked. Yet researchers and clinicians have historically underrecognized this connection.
Too often, heart disease in women is framed as a late-life problem or a “man’s disease.” Many assume it appears suddenly. In reality, cardiovascular disease develops over decades of biological and hormonal change.
The 2025 European Heart Journal review challenges how we understand women’s heart health across the lifespan.
A Landmark Review With Global Impact
In December 2025, the European Heart Journal published a landmark review titled “Cardiovascular disease in women: traditional and sex-specific risk factors.” The authors synthesized decades of research to examine how cardiovascular risk develops, accelerates, and compounds throughout a woman’s life.
This paper is not a single study. It is a comprehensive retrospective analysis of large, long-term, multinational cohort studies. Researchers followed hundreds of thousands of women over many years — and in some cases, decades.
Because of this scope, the findings extend far beyond geography. The conclusions apply broadly to women’s health worldwide and carry significant implications for clinical care.
Why Longitudinal Data Matters for Women
Longitudinal studies follow individuals over time. They reveal patterns that short-term or cross-sectional studies cannot detect.
In women’s health, this approach is essential. Hormonal biology does not remain static. It changes repeatedly across the lifespan, and disease risk changes with it.
The studies analyzed in this review tracked women through puberty, reproductive years, pregnancy, perimenopause, menopause, and postmenopause. By examining outcomes across these stages, researchers identified early warning signals that often precede clinical disease by many years.
For this reason, longitudinal data plays a critical role in understanding women’s cardiovascular risk.
Hormonal Transitions Shape Cardiovascular Risk
One of the most important insights from this review is clear: women’s cardiovascular risk is deeply intertwined with hormonal transitions.
Puberty: The First Shift
Puberty introduces dramatic changes in estrogen, progesterone, insulin sensitivity, fat distribution, and inflammatory signaling. These changes influence lipid metabolism, vascular function, and blood pressure. For some women, early hormonal disruption may set the stage for later cardiometabolic risk.
Reproductive Years and Pregnancy
Pregnancy acts as a cardiovascular stress test. Conditions such as preeclampsia, gestational diabetes, and hypertensive disorders of pregnancy serve as early markers of future cardiovascular disease. These are not isolated events that end after delivery.
Perimenopause: A Critical Inflection Point
Perimenopause represents a major turning point. Fluctuating estrogen levels during this transition drive changes in lipid profiles, visceral fat accumulation, insulin resistance, and inflammation. The symptoms women experience during this phase may signal emerging cardiovascular vulnerability.
Menopause and Postmenopause
After menopause, sustained estrogen deficiency contributes to endothelial dysfunction, accelerated atherosclerosis, rising blood pressure, and increased inflammatory burden. Importantly, cardiovascular risk does not suddenly appear at menopause. It accumulates across decades of hormonal change.
Longitudinal data now show that hormonal changes and heart disease in women are connected across the entire lifespan.
Why Traditional Risk Models Miss Women
For decades, cardiovascular risk assessment relied on models developed primarily from male populations. These models emphasize LDL cholesterol, smoking, and hypertension.
While important, these markers fail to capture the full picture for women — especially during midlife transitions.
The European Heart Journal review highlights additional sex-specific risk enhancers, including hormonal history, reproductive events, metabolic and inflammatory changes, autoimmune disease prevalence, and chronic stress and caregiving burden.
When clinicians fail to integrate these factors, diagnosis occurs later, prevention opportunities are missed and women’s heart health across the lifespan descreases.
A Turning Point in Women’s Cardiovascular Care
This research marks a turning point. It shows that risk begins earlier than symptoms. Hormonal transitions provide critical clues. Longitudinal data reveals patterns that short-term studies overlook.
As a result, the evidence supports a shift from reactive treatment to earlier, personalized prevention. A woman’s hormonal and metabolic history should guide that prevention.
Women today will spend more years of their lives postmenopausal than any previous generation. Yet many are never taught how hormonal changes influence long-term disease risk — or how to advocate for appropriate evaluation.
Why Education and Empowerment Matter
At Thrive for Longevity, we believe informed women change outcomes.
That belief drives our work. We break down complex data into clear education. We explain which biomarkers matter and why. We help women prepare for informed conversations with their healthcare providers.
When women understand how their bodies change over time, they gain the power to lead their own preventive care.
This overview article serves as the foundation for a series of in-depth journal articles aligned with Thrive for Longevity’s pillars of wellness. Each article will explore one dimension of cardiovascular risk in women and translate evidence into real-world relevance.
Our goal is not to overwhelm.
It is to empower women with clarity, confidence, and evidence.
